Have you heard about an eye condition that can lead to irreversible vision loss if not treated on time? Glaucoma is a group ...

Glaucoma is often referred to as the "silent thief of sight" because it typically progresses slowly and without noticeable ...

Glaukos (NYSE:GKOS) stock is up on upgrade to Buy from Hold at Jefferies on strong iDose Outlook. “We are upgrading GKOS shares to Buy from Hold following positive proprietary survey takes which ...

Q1 2024 Earnings Call Transcript May 5, 2024 Sight Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds ...

Travoprost Ophthalmic Solution USP, 0.004% (RLD Travatan Z), had estimated annual sales of USD 77 million in the U.S. (IQVIA MAT March 2024).

Swiss-American ophthalmology company Alcon (SWX: ALC) is acquiring Israeli glaucoma treatment company Belkin Vision for up to ...

The anticipated near-term sales growth inflection for iDose, combined with the sustained performance of Glaukos’s core glaucoma and corneal health franchises, underpins the upgrade to a Buy rating.

A recent study from Duke University suggest that higher body mass index (BMI) may help slow the progression of glaucoma which ...

Diseases are bad news, and when one has gained notoriety like the way glaucoma is prevalent in Ghana, it calls for a lot of ...

(MENAFN- Andrew Lloyd & Associates) Ciliatech’s glaucoma implant CID receives favorable opinion on treating both open and narrow angle forms of disease First independent observations, presented by Dr.

Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and ...

Travoprost ophthalmic solution USP, 0.004%, is specifically indicated for the reduction of elevated intraocular pressure in ...